- Lead Products
- Early Stage Products
- Intellectual Property
- Press Room
- Contact Us
Foamix Announces Positive Results from Phase I Study to Characterize Minocycline Bioavailability of FMX-101 Compared to Solodyn® (Minocycline HCl) Extended-Release TabletsRead more...
Foamix to Present Corporate Overview at the 3rd Annual Dermatology Summit MeetingRead more...
Foamix Announces Positive Top-Line Results from Phase II Study for FDX104 (Doxycycline Foam) in the Prevention of Acneiform Rash Associated with Targeted Antibody Treatments for Colon and Head and Neck CancersRead more...